Niagen Bioscience

Niagen Bioscience is the rare profitable, public pure-play on the NAD+ thesis, and its 2025 numbers show a genuine inflection rather than a story stock. Formerly ChromaDex, the Los Angeles company rebranded to Niagen Bioscience (Nasdaq: NAGE) in March 2025 to center itself on healthy aging, and full-year 2025 revenue rose roughly 30% to about $129M with net income more than doubling to over $17M — real earnings, expanding gross margins around 64%, a $64M cash position, and no debt. The growth is broad-based: Tru Niagen, its direct-to-consumer supplement built on patented Niagen nicotinamide riboside, grew strongly (Q3 2025 Tru Niagen sales up 44%), while the ingredient and distribution business surged (Q1 pharmaceutical-and-food-grade Niagen ingredient sales up 95%, Q3 distribution up over 100%), giving the company two engines — a consumer brand and an upstream ingredient franchise supplying the broader NAD+ market. That dual position is the moat: Niagen owns a patented, clinically studied NR molecule with published human research behind it, sells it under a brand it positions as the #1 NAD+ supplement in the US, and simultaneously licenses the ingredient into competitors' products and supplies analytical reference standards. As NAD+ crosses from niche into mainstream longevity and IV-drip clinics proliferate, Niagen is the picks-and-shovels supplier with IP protection, GRAS/NDI regulatory standing that many NMN sellers lack, and the profitability to out-market a fragmented field.

Niagen's fortunes are chained to a single molecule and a single scientific narrative: if rigorous human trials continue to fail to show that raising NAD+ meaningfully extends healthspan or lifespan, the entire category — Tru Niagen included — is a wellness fad living on marketing rather than proven benefit, and the stock's re-rating on the "healthy aging" story unwinds. The competitive and legal terrain is treacherous. ChromaDex spent years in costly patent litigation with Elysium Health, and NR's IP is perpetually contested; meanwhile NMN — a rival NAD+ precursor — floods the market cheaper, even as its ambiguous FDA supplement status creates category-wide regulatory overhang that could cut either way. Supplement businesses live and die on customer acquisition cost and churn, and Tru Niagen competes for the same longevity dollar against NMN sellers, Jinfiniti's test-and-supplement model, and every DTC brand riding the NAD+ wave. The IV-NAD+ clinic boom is a fashion with thin evidence and real safety questions that could invite FDA attention and tarnish the whole NAD+ complex. At a valuation that now embeds 30% growth and margin expansion continuing, any deceleration in Tru Niagen, a patent setback, or a damaging clinical readout on NAD+ efficacy would compress both earnings and multiple simultaneously. A profitable niche supplier today, Niagen is one negative NAD+ trial away from being a commodity ingredient business in a category whose core premise never got proven.